.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,521,184

« Back to Dashboard

Claims for Patent: 5,521,184

Title: Pyrimidine derivatives and processes for the preparation thereof
Abstract:There are described N-phenyl-2-pyrimidine-amine derivatives of formula I ##STR1## wherein R.sub.1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen, R.sup.2, R.sup.3, R.sup.9, X, Y, n and R.sup.10 are defined in claim 1 These compounds can be used, for example, in the therapy of tumoral diseases.
Inventor(s): Zimmermann; Jurg (Wallbach, CH)
Assignee: Ciba-Geigy Corporation (Tarrytown, NY)
Application Number:08/234,889
Patent Claims: 1. An N-phenyl-2-pyrimidine-amine compound of formula I ##STR9## wherein R.sub.1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen,

R.sub.2 and R.sub.3 are each independently of the other hydrogen or lower alkyl, one or two of the radicals R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each nitro, fluoro-substituted lower alkoxy or a radical of formula II

wherein

R.sub.9 is hydrogen or lower alkyl,

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydroximino,

Y is oxygen or the group NH,

n is 0 or 1 and

R.sub.10 is an aliphatic radical having at least 5 carbon atoms, or an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or hetero-cyclicaliphatic radical,

and the remaining radicals R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified or esterifed hydroxy, free, alkylated or acylated amino or free or esterified carboxy,

or a salt of such a compound having at least one salt-forming group.

2. A compound of formula I according to claim 1, wherein one or two of the radicals R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each nitro or a radical of formula II

wherein

R.sub.9 is hydrogen or lower alkyl,

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydroximino,

Y is oxygen or the group NH,

n is 0 or 1 and

R.sub.10 is an aliphatic radical having at least 5 carbon atoms or an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or hetero-cyclicaliphatic radical,

and the remaining radicals R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified or esterifed hydroxy, free, alkylated or acylated amino or free or esterified carboxy,

and the remaining substituents are as defined in claim 1,

or a salt of such a compound having at least one salt-forming group.

3. A compound of formula I according to claim 1,

wherein

R.sub.1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated by one or two lower alkyl radicals or acylated by lower alkanoyl or by benzoyl, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen,

R.sub.2 and R.sub.3 are each independently of the other hydrogen or lower alkyl, one or two of the radicals R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each nitro, fluoro-substituted lower alkoxy or a radical of formula II wherein

R.sub.9 is hydrogen or lower alkyl,

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydroximino,

Y is oxygen or the group NH,

n is 0 or 1 and

R.sub.10 is an aliphatic hydrocarbon radical having 5-22 carbon atoms, a phenyl or naphthyl radical each of which is unsubstituted or substituted by cyano, lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, (4-methyl-piperazinyl)-lower alkyl, trifluoromethyl, hydroxy, lower alkoxy, lower alkanoyloxy, halogen, amino, lower alkylamino, di-lower alkylamino, lower alkanoylamino, benzoylamino, carboxy or by lower alkoxycarbonyl, or phenyl-lower alkyl wherein the phenyl radical is unsubstituted or substituted as indicated above, a cycloalkyl or cycloalkenyl radical having up to 30 carbon atoms, cycloalkyl-lower alkyl or cycloalkenyl-lower alkyl each having up to 30 carbon atoms in the cycloalkyl or cycloalkenyl moiety, a monocyclic radical having 5 or 6 ring members and 1-3 ring hetero atoms selected from nitrogen, oxygen and sulfur, to which radical one or two benzene radicals may be fused, or lower alkyl substituted by such a monocyclic radical,

and the remaining radicals R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by amino, lower alkylamino, di-lower alkylamino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, hydroxy, lower alkoxy, lower alkanoyloxy, halogen, amino, lower alkylamino, di-lower alkylamino, lower alkanoylamino, benzoylamino, carboxy or lower alkoxycarbonyl,

or a salt of such a compound having at least one salt-forming group.

4. A compound of formula I according to claim 1,

wherein

R.sub.1 is pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen,

R.sub.2 and R.sub.3 are each hydrogen,

R.sub.4 is hydrogen or lower alkyl,

R.sub.5 is hydrogen, lower alkyl or fluoro-substituted lower alkoxy,

R.sub.6 is hydrogen,

R.sub.7 is nitro, fluoro-substituted lower alkoxy or a radical of formula II wherein

R.sub.9 is hydrogen,

X is oxo,

n is 0 and

R.sub.10 is an aliphatic hydrocarbon radical having 5-22 carbon atoms, a phenyl radical that is unsubstituted or substituted by cyano, lower alkyl, (4-methyl-piperazinyl)-lower alkyl, lower alkoxy, halogen or by carboxy; a cycloalkyl radical having up to 30 carbon atoms or a monocyclic radical having 5 or 6 ring members and 1-3 sulfur ring atoms, and

R.sub.8 is hydrogen,

or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

5. A compound of formula I according to claim 1,

wherein

R.sub.1 is pyridyl or N-oxido-pyridyl each of which is bonded at a carbon atom,

R.sub.2 and R.sub.3 are each hydrogen,

R.sub.4 is hydrogen or lower alkyl,

R.sub.5 is hydrogen, lower alkyl or trifluoromethyl,

R.sub.6 is hydrogen,

R.sub.7 is nitro, fluoro-substituted lower alkoxy or a radical of formula II wherein

R.sub.9 is hydrogen,

X is oxo,

n is the number 0 and

R.sub.10 is pyridyl bonded at a carbon atom, phenyl that is unsubstituted or substituted by halogen, cyano, lower alkoxy, carboxy, lower alkyl or by 4-methyl-piperazinylmethyl, or C.sub.5 -C.sub.7 alkyl, thienyl, 2-naphthyl or cyclohexyl, and

R.sub.8 is hydrogen,

or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

6. A compound according to claim 1 of formula I, wherein R.sub.4 and R.sub.8 are each hydrogen and the remaining substituents are as defined in claim 1, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

7. A compound according to claim 3 of formula I, wherein R.sub.4 and R.sub.8 are each hydrogen and the remaining substituents are as defined in claim 3, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

8. A compound according to claim 4 of formula I, wherein R.sub.4 and R.sub.8 are each hydrogen and the remaining substituents are as defined in claim 4, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

9. A compound according to claim 5 of formula I, wherein R.sub.4 and R.sub.8 are each hydrogen and the remaining substituents are as defined in claim 5, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

10. A compound according to claim 1 of formula I, wherein at least one of the radicals R.sub.4 and R.sub.8 is lower alkyl, and the remaining substituents are as defined in claim 1, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

11. A compound according to claim 3 of formula I, wherein at least one of the radicals R.sub.4 and R.sub.8 is lower alkyl, and the remaining substituents are as defined in claim 3, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

12. A compound according to claim 4 of formula I, wherein at least one of the radicals R.sub.4 and R.sub.8 is lower alkyl, and the remaining substituents are as defined in claim 4, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

13. A compound according to claim 5 of formula I, wherein at least one of the radicals R.sub.4 and R.sub.8 is lower alkyl, and the remaining substituents are as defined in claim 5, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

14. A compound according to claim 1 of formula I,

wherein

R.sub.1 is pyridyl bonded at a carbon atom,

R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.8 are each hydrogen and

R.sub.7 is nitro or a radical of formula II wherein

R.sub.9 is hydrogen,

X is oxo,

n is the number 0 and

R.sub.10 is pyridyl bonded at a carbon atom, phenyl that is unsubstituted or substituted by fluorine, chlorine, cyano, lower alkoxy, carboxy, lower alkyl or by 4-methyl-piperazinyl-methyl, or C.sub.5 -C.sub.7 alkyl, thienyl or cyclohexyl,

or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 1 of formula I, wherein R.sub.1 is 4-pyridyl, N-oxido-4-pyridyl, or 3-indolyl, and R.sub.7 is fluoro-substituted alkoxy containing up to 2 carbon atoms, or a salt of such a compound containing at least one salt-forming group.

16. A compound of formula I according to claim 1, wherein R.sub.1 is 4-pyridyl, N-oxido-4-pyridyl, or 3-indolyl, and R.sub.7 is trifluoromethoxy or 1,1,2,2-tetrafluoroethoxy, or a salt of such a compound containing at least one salt-forming group.

17. N-(5-Benzoylamido-2-methyl-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine or a pharmaceutically acceptable salt thereof according to claim 1.

18. N-[3-(1,1,2,2-Tetrafluoroethoxy)phenyl]-4-(4-pyridyl)-2-pyrim idine-amine or a pharmaceutically acceptable salt thereof according to claim 1.

19. A compound according to claim 1 of the formula I or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group selected from N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(4-Chlorobenzoylamido)-phenyl]-4-(3-pyridyl)-2--pyrimidine-amine,

N-(3-Benzoylamido-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(2-Pyridyl)carboxamido-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(3-pyridyl)carboxamido-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(4-pyridyl)carboxamido-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-Pentafluoro-benzoylamido-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(2-Carboxy-benzoylamido )-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-n-Hexanoylamido-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-Nitro-phenyl)-4-(2-pyridyl)-2-pyrimidine-amine,

N-(3-Nitro-phenyl)-4-(4-pyridyl)-2-pyrimidine-amine,

N-[3-(2-Methoxy-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(4-Fluoro-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(4-Cyano-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(2-Thienylcarboxamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-Cyclohexycarboxamido-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(4-Methyl-benzoylamido)-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-[3-(4-Chloro-benzoylamido)-phenyl]-4-(4-pyridyl)-2-pyrimidine-amine,

N-{3-[4-(4-Methyl-piperazinomethyl)-benzoylamido]-phenyl}-4-(3-pyridyl)-2-p yrimidine-amine,

N-[5-(4-Methyl-benzoylamido)-2-methyl-phenyl]-4-(3-pyridyl)-2-pyrimidine-am ine,

N-[5-(2-Naphthoylamido )-2-methyl-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-[5-(4-Chloro-benzoylamido )-2-methyl-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-[5-(2-Methoxy-benzoylamido )-2-methyl-phenyl]-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-Trifluoromethoxy-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-[1,1,2,2-tetrafluoro-ethoxy]-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-Nitro-5-methyl-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-Nitro-5-trifluoromethyl-phenyl)-4-(3-pyridyl)-2-pyrimidine-amine,

N-(3-Nitro-phenyl)-4-(N-oxido-3-pyridyl)-2-pyrimidine-amine,

N-(3-Benzoylamido-5-methyl-phenyl)-4-(N-oxido-3-pyridyl)-2-pyrimidine-amine and the pharmaceutically acceptable salts of such a compound having at least one salt-forming group.

20. A compound according to claim 1 of the formula I or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group selected from N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-(N-oxido-4-pyridyl)-2-pyrimidine -amine and N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-(3-indolyl)-2-pyrimidine-amine and the pharmaceutically acceptable salts of such a compound having at least one salt-forming group.

21. A pharmaceutical composition for the treatment of tumours in warm-blooded animals including humans, comprising, in a dose effective against tumours, a compound of formula I according to claim 1, or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group, together with a pharmaceutical carrier.

22. A method of treating warm-blooded animals including humans, which comprises administering to such a warm-blooded animal suffering from a tumoral disease a dose, effective against tumours, of a compound of formula I according to claim 1 or of a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

23. The compound according to claim 1 of the formula I, said compound being N-{5-[4-(4-Methyl-piperazino-methyl)-benzoylamido]-2-methyl-phenyl}-4-(3-p yridyl)-2-pyrimidine-amine or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc